SubHero Banner

Winrevair (sotatercept) – New orphan drug approval

March 26, 2024 - Merck announced the FDA approval of Winrevair (sotatercept-csrk), for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events.

Download PDF